Xin Zhong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xin Zhong has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Minjie Wei
Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
8 shared publications - Mingyan Liu
Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
5 shared publications Menglin Gao
School of Pharmacy, China Medical University, Shenyang, China
4 shared publicationsHuachao Jia
School of Pharmacy, China Medical University, Shenyang, China
3 shared publications- Zhihua Yu
Department of Neurology, the Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning 110032, China
3 shared publications Fan Zhang
School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, China
2 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Elsevier in Pharmacological Research
- Vol. 228, 108216
Organelle-orchestrated cGAS-STING signaling and its role in neurodegeneration
- 1 May 2026
- Published by Elsevier in Pharmacological Research
- Vol. 228, 108216
Open AccessOrganelle-orchestrated cGAS-STING signaling and its role in neurodegeneration
- Top Cited PapersOpen Access
- 3 January 2026
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 21 (1)
Organelle stress in NLRP3 inflammasome: a central mediator of neurodegenerative diseases
Organelle stress and NLRP3 inflammasome activation have been established as pivotal contributors to inflammatory responses and play a significant role in t
- 3 January 2026
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 21 (1)
Top Cited PapersOpen AccessOrganelle stress in NLRP3 inflammasome: a central mediator of neurodegenerative diseases
Organelle stress and NLRP3 inflammasome activation have been established as pivotal contributors to inflammatory responses and play a significant role in t
- Open Access
- 26 November 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 86, 767-784
Novel protein acylations in Alzheimer’s disease: Molecular, mechanisms, biological significance, and diagnostic and therapeutic potentials
- 26 November 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 86, 767-784
Open AccessNovel protein acylations in Alzheimer’s disease: Molecular, mechanisms, biological significance, and diagnostic and therapeutic potentials
- Open Access
- 16 July 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 82, 1115-1132
Organelle regulation of SUMOylation: regulatory mechanisms and therapeutic application
- 16 July 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 82, 1115-1132
Open AccessOrganelle regulation of SUMOylation: regulatory mechanisms and therapeutic application
- Open Access
- 24 December 2024
- Published by Springer Nature in Translational Neurodegeneration
- Vol. 13 (1) , 1-29
Endosomal traffic disorders: a driving force behind neurodegenerative diseases
Endosomes are crucial sites for intracellular material sorting and transportation. Endosomal transport is a critical process involved in the selective uptake, processing, and intracellular transport of substances. The equilibrium between endocytosis and circulation mediated by the endosome-centered transport pathway plays a significant role in cell homeostasis, signal transduction, and immune response. In recent years, there have been hints linking endosomal transport abnormalities to neurodegenerative diseases, including Alzheimer's disease. Nonetheless, the related mechanisms remain unclear. Here, we provide an overview of endosomal-centered transport pathways and highlight potential physiological processes regulated by these pathways, with a particular focus on the correlation of endosomal trafficking disorders with common pathological features of neurodegenerative diseases. Additionally, we summarize potential therapeutic agents targeting endosomal trafficking for the treatment of neurodegenerative diseases. Graphical abstract
- 24 December 2024
- Published by Springer Nature in Translational Neurodegeneration
- Vol. 13 (1) , 1-29
Open AccessEndosomal traffic disorders: a driving force behind neurodegenerative diseases
Endosomes are crucial sites for intracellular material sorting and transportation. Endosomal transport is a critical process involved in the selective uptake, processing, and intracellular transport of substances. The equilibrium between endocytosis and circulation mediated by the endosome-centered transport pathway plays a significant role in cell homeostasis, signal transduction, and immune response. In recent years, there have been hints linking endosomal transport abnormalities to neurodegenerative diseases, including Alzheimer's disease. Nonetheless, the related mechanisms remain unclear. Here, we provide an overview of endosomal-centered transport pathways and highlight potential physiological processes regulated by these pathways, with a particular focus on the correlation of endosomal trafficking disorders with common pathological features of neurodegenerative diseases. Additionally, we summarize potential therapeutic agents targeting endosomal trafficking for the treatment of neurodegenerative diseases. Graphical abstract
- Open Access
- 1 May 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116646
Early signs of neurodegenerative diseases: Possible mechanisms and targets for Golgi stress
- 1 May 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116646
Open AccessEarly signs of neurodegenerative diseases: Possible mechanisms and targets for Golgi stress
- Open Access
- 30 November 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 157, 114054
Cordycepin improved neuronal synaptic plasticity through CREB-induced NGF upregulation driven by MG-M2 polarization: a microglia-neuron symphony in AD
- 30 November 2022
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 157, 114054
Open AccessCordycepin improved neuronal synaptic plasticity through CREB-induced NGF upregulation driven by MG-M2 polarization: a microglia-neuron symphony in AD
- Open Access
- 18 May 2022
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 14, 899175
Association of Circulating Apolipoprotein AI Levels in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis
With the development of medicine, our research on Alzheimer's disease (AD) has been further deepened, but the mechanism of its occurrence and development has not been fully revealed, and there is currently no effective treatment method. Several studies have shown that apolipoprotein AI (ApoA-I) can affect the occurrence and development of Alzheimer's disease by binding to amyloid β (Aβ). However, the association between circulating levels of ApoA-I and AD remains controversial. We conducted a meta-analysis of 18 studies published between 1992 and 2017 to determine whether the ApoA-I levels in the blood and cerebrospinal fluid (CSF) are abnormal in AD. Literatures were searched in PubMed, EMBASE and Web of Science databases without language limitations. A pooled subject sample including 1,077 AD patients and 1,271 healthy controls (HCs) was available to assess circulating ApoA-I levels; 747 AD patients and 680 HCs were included for ApoA-I levels in serum; 246 AD patients and 456 HCs were included for ApoA-I levels in plasma; 201 AD patients and 447 HCs were included for ApoA-I levels in CSF. It was found that serum and plasma levels of ApoA-I were significantly reduced in AD patients compared with HCs {[standardized mean difference (SMD) = −1.16; 95% confidence interval (CI) (−1.72, −0.59); P = 0.000] and [SMD = −1.13; 95% CI (−2.05, −0.21); P = 0.016]}. Patients with AD showed a tendency toward higher CSF ApoA-I levels compared with HCs, although this difference was non-significant [SMD = 0.20; 95% CI (−0.16, 0.56); P = 0.273]. In addition, when we analyzed the ApoA-I levels of serum and plasma together, the circulating ApoA-I levels in AD patients was significantly lower [SMD = −1.15; 95% CI (−1.63, −0.66); P = 0.000]. These results indicate that ApoA-I deficiency may be a risk factor of AD, and ApoA-I has the potential to serve as a biomarker for AD and provide experimental evidence for diagnosis of AD.Systematic Review Registration: PROSPERO, identifier: 325961.
- 18 May 2022
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 14, 899175
Open AccessAssociation of Circulating Apolipoprotein AI Levels in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis
With the development of medicine, our research on Alzheimer's disease (AD) has been further deepened, but the mechanism of its occurrence and development has not been fully revealed, and there is currently no effective treatment method. Several studies have shown that apolipoprotein AI (ApoA-I) can affect the occurrence and development of Alzheimer's disease by binding to amyloid β (Aβ). However, the association between circulating levels of ApoA-I and AD remains controversial. We conducted a meta-analysis of 18 studies published between 1992 and 2017 to determine whether the ApoA-I levels in the blood and cerebrospinal fluid (CSF) are abnormal in AD. Literatures were searched in PubMed, EMBASE and Web of Science databases without language limitations. A pooled subject sample including 1,077 AD patients and 1,271 healthy controls (HCs) was available to assess circulating ApoA-I levels; 747 AD patients and 680 HCs were included for ApoA-I levels in serum; 246 AD patients and 456 HCs were included for ApoA-I levels in plasma; 201 AD patients and 447 HCs were included for ApoA-I levels in CSF. It was found that serum and plasma levels of ApoA-I were significantly reduced in AD patients compared with HCs {[standardized mean difference (SMD) = −1.16; 95% confidence interval (CI) (−1.72, −0.59); P = 0.000] and [SMD = −1.13; 95% CI (−2.05, −0.21); P = 0.016]}. Patients with AD showed a tendency toward higher CSF ApoA-I levels compared with HCs, although this difference was non-significant [SMD = 0.20; 95% CI (−0.16, 0.56); P = 0.273]. In addition, when we analyzed the ApoA-I levels of serum and plasma together, the circulating ApoA-I levels in AD patients was significantly lower [SMD = −1.15; 95% CI (−1.63, −0.66); P = 0.000]. These results indicate that ApoA-I deficiency may be a risk factor of AD, and ApoA-I has the potential to serve as a biomarker for AD and provide experimental evidence for diagnosis of AD.Systematic Review Registration: PROSPERO, identifier: 325961.